MedTrace Logo

Effect of Vitamin D Treatment in Primary Hyperparathyroidism

NCT00674154 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2013-11-18

Study results available
· View outcomes & findings →

Summary

The primary aim of the study is to assess whether 6-months of vitamin D supplements can decrease PTH compared with placebo treatment in primary hyperparathyroidism.

Conditions

  • Vitamin D Deficiency
  • Primary Hyperparathyroidism
  • Hypercalcemia

Interventions

DRUG

Cholecalciferol

2800 IE daily in 52 weeks

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Lars Rolighed, MD

  • Lars Rejnmark, MD,PhD,DrMed

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00674154 on ClinicalTrials.gov